We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Retain IQV Stock in Your Portfolio Now
Read MoreHide Full Article
Key Takeaways
IQV gained 25.5% in three months, outpacing the industry's 12.1% rise.
IQV named AWS its Preferred Agentic Cloud Provider to accelerate clinical trial automation and analytics.
IQV's R&DS backlog hit $32.4B, with $8.1B converting to revenues over the next 12 months.
IQVIA Holdings, Inc. (IQV - Free Report) has gained 25.5% over the past three months compared with the industry’s 12.1% rise.
The company has an expected long-term EPS (three to five years) growth rate of 8.38%. Earnings are expected to register year-over-year growth of 6.9% in 2025 and 8.4% in 2026.
Image Source: Zacks Investment Research
Factors That Augur Well for IQVIA’s Success
IQVIA’s collaboration with Amazon Web Services ("AWS") strengthens its position at the intersection of life sciences and advanced AI. By naming AWS as its Preferred Agentic Cloud Provider, IQVIA secures access to a scalable, secure and mature cloud ecosystem that can accelerate clinical trial automation and advanced analytics. The partnership also strengthens IQVIA’s competitive moat, as most leading pharmaceutical companies already rely on both platforms. Over time, this alliance can improve operating efficiency, shorten drug development timelines and increase client stickiness, positioning IQVIA to benefit from the growing adoption of agentic AI across the healthcare and life sciences value chain.
In the third quarter of 2025, IQV’s expanding R&DS backlog was $32.4 billion, up 4.1% year over year, which provides strong revenue visibility, with $8.1 billion expected to convert to revenues over the next 12 months.
Book-to-bill ratios remained healthy, with 1.15X in the third quarter and 1.12X on a trailing-12-month basis, indicating that bookings continue to outpace revenue recognition and support future growth. In addition, net new bookings of $2.6 billion and 13% year-over-year growth in R&DS net bookings, alongside 20% year-over-year growth in RFP activity, point to strengthening client demand and improving decision timelines. These trends reinforce confidence in sustained revenue momentum into 2026.
The company has demonstrated a strong commitment to returning value to its shareholders through an active share repurchase program. In 2024, IQV repurchased shares worth $1.35 billion. Over the nine-month period ending in 2025, the company has repurchased shares worth $1.03 billion. This substantial buyback not only lowers the total outstanding share count and boosts earnings per share (EPS) but also signals management's belief in the intrinsic value of the stock.
IQV’s Key Risks to Watch
IQV is facing significant challenges from weak liquidity. The company’s current ratio (a measure of liquidity) is consistently falling, declining from 1.12 in 2020 to 0.91 in 2021 and 0.89 in 2022, reflecting tightening working capital. The ratio slipped further to 0.86 in 2023 and 0.84 in 2024, before dropping sharply to 0.70 in the third quarter of 2025, underscoring growing pressure on short-term financial flexibility and a heavier reliance on cash flow to meet near-term obligations. A current ratio of less than one is considered undesirable as it indicates that the company does not have sufficient cash to meet its short-term obligations.
IQV’s Zacks Rank
IQV currently carries a Zacks Rank of #3 (Hold).
Stocks to Consider
A couple of better-ranked stocks are Byrna Technologies (BYRN - Free Report) and Veralto Corporation (VLTO - Free Report) .
Byrna Technologies currently carries a Zacks Rank of 2 (Buy). BYRN has an expected earnings growth rate of 25.8% and 33.3% for 2025 and 2026, respectively.
BYRN has an encouraging earnings surprise history as it has surpassed the Zacks Consensus Estimate in the trailing four quarters, delivering an average earnings surprise of 167.5%.
VLTO has expected earnings growth rates of 8.5% and 9.2% for 2025 and 2026, respectively. The company has an encouraging earnings surprise history as it has surpassed the Zacks Consensus Estimate in the trailing four quarters, delivering an average earnings surprise of 6.5%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why You Should Retain IQV Stock in Your Portfolio Now
Key Takeaways
IQVIA Holdings, Inc. (IQV - Free Report) has gained 25.5% over the past three months compared with the industry’s 12.1% rise.
The company has an expected long-term EPS (three to five years) growth rate of 8.38%. Earnings are expected to register year-over-year growth of 6.9% in 2025 and 8.4% in 2026.
Image Source: Zacks Investment Research
Factors That Augur Well for IQVIA’s Success
IQVIA’s collaboration with Amazon Web Services ("AWS") strengthens its position at the intersection of life sciences and advanced AI. By naming AWS as its Preferred Agentic Cloud Provider, IQVIA secures access to a scalable, secure and mature cloud ecosystem that can accelerate clinical trial automation and advanced analytics. The partnership also strengthens IQVIA’s competitive moat, as most leading pharmaceutical companies already rely on both platforms. Over time, this alliance can improve operating efficiency, shorten drug development timelines and increase client stickiness, positioning IQVIA to benefit from the growing adoption of agentic AI across the healthcare and life sciences value chain.
In the third quarter of 2025, IQV’s expanding R&DS backlog was $32.4 billion, up 4.1% year over year, which provides strong revenue visibility, with $8.1 billion expected to convert to revenues over the next 12 months.
Book-to-bill ratios remained healthy, with 1.15X in the third quarter and 1.12X on a trailing-12-month basis, indicating that bookings continue to outpace revenue recognition and support future growth. In addition, net new bookings of $2.6 billion and 13% year-over-year growth in R&DS net bookings, alongside 20% year-over-year growth in RFP activity, point to strengthening client demand and improving decision timelines. These trends reinforce confidence in sustained revenue momentum into 2026.
The company has demonstrated a strong commitment to returning value to its shareholders through an active share repurchase program. In 2024, IQV repurchased shares worth $1.35 billion. Over the nine-month period ending in 2025, the company has repurchased shares worth $1.03 billion. This substantial buyback not only lowers the total outstanding share count and boosts earnings per share (EPS) but also signals management's belief in the intrinsic value of the stock.
IQV’s Key Risks to Watch
IQV is facing significant challenges from weak liquidity. The company’s current ratio (a measure of liquidity) is consistently falling, declining from 1.12 in 2020 to 0.91 in 2021 and 0.89 in 2022, reflecting tightening working capital. The ratio slipped further to 0.86 in 2023 and 0.84 in 2024, before dropping sharply to 0.70 in the third quarter of 2025, underscoring growing pressure on short-term financial flexibility and a heavier reliance on cash flow to meet near-term obligations. A current ratio of less than one is considered undesirable as it indicates that the company does not have sufficient cash to meet its short-term obligations.
IQV’s Zacks Rank
IQV currently carries a Zacks Rank of #3 (Hold).
Stocks to Consider
A couple of better-ranked stocks are Byrna Technologies (BYRN - Free Report) and Veralto Corporation (VLTO - Free Report) .
Byrna Technologies currently carries a Zacks Rank of 2 (Buy). BYRN has an expected earnings growth rate of 25.8% and 33.3% for 2025 and 2026, respectively.
BYRN has an encouraging earnings surprise history as it has surpassed the Zacks Consensus Estimate in the trailing four quarters, delivering an average earnings surprise of 167.5%.
Veralto Corporation carries a Zacks Rank of 2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
VLTO has expected earnings growth rates of 8.5% and 9.2% for 2025 and 2026, respectively. The company has an encouraging earnings surprise history as it has surpassed the Zacks Consensus Estimate in the trailing four quarters, delivering an average earnings surprise of 6.5%.